The infrastructure moment for AI-driven drug discovery continues to accelerate, with billion-dollar investments flowing into ...
Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...
Xaira is an integrated biotechnology company built to deliver on the promise of AI to help transform the drug discovery and development process Dr. Ian McCaffery joins from AbbVie, where he served as ...
Design of targeted protein degraders is more than target degradation. Linker architecture, molecular flexibility, solubility, permeability, synthesis, purification, and formulation can all influence ...
Key Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering StrategyImmuron is seeking a partner to support ...
Syntara (ASX:SNT) has reported encouraging interim results from its Phase 2 study of SNT-4728, providing the first clinical ...
Introducing Claude Science, the AI platform designed to expedite the discovery of promising new therapies. Anthropic will ...
Anthropic also went a step further, saying it would develop drugs of its own. Head of life sciences Eric Kauderer-Abrams said ...
When life sciences startups think about patent strategy, the natural instinct is to focus on the core science — the novel compound, the ...
Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced successful results ...
The Hearty Soul on MSN
A drug that lets you grow new teeth is now in human trials
A drug targeting the USAG-1 protein entered human trials in Japan in 2024. Researchers aim to make third tooth regrowth ...
Discover how automation, AI, and organoid technologies are improving drug discovery through scalable workflows.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results